AKT-induced reactive oxygen species generate imatinib-resistant clones emerging from chronic myeloid leukemia progenitor cells

This publication has 15 references indexed in Scilit:

• Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy
  Proceedings of the National Academy of Sciences, 2014
• Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells
  Blood, 2013
• Anti-oxidant vitamin E prevents accumulation of imatinib-resistant BCR-ABL1 kinase mutations in CML-CP xenografts in NSG mice
  Leukemia, 2013
• Rac2-MRC-cIII–generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors
  Blood, 2012
• Chronic myeloid leukemia: mechanisms of blastic transformation
  Journal of Clinical Investigation, 2010
• Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors
  Leukemia, 2008
• Chronic myeloid leukaemia: stem cell derived but progenitor cell driven
  Clinical Science, 2005
• Activation of the PI3K/mTOR pathway by BCR-ABL contributes to increased production of reactive oxygen species
  Blood, 2005
• Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia
  Biochemical and Biophysical Research Communications, 2004
• Transformation of hematopoietic cells by BCR/ABL requires activation of a PI‐3k/Akt‐dependent pathway
  The EMBO Journal, 1997